Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown to extend overall survival and progression-free survival of newly diagnosed patients with glioblastoma multiforme (GBM). Optune is a portable, noninvasive device that delivers low-intensity, alternating electric fields (referred to as Tumor Treating Fields) that inhibit cancer cell replication and cause cancer cells to die.
Willis-Knighton was pleased to learn that the Caddo Parish School Board has accepted its bid for the Hamilton Terrace school property.
In January Willis-Knighton Cancer Center joins leading cancer centers in the United States in a new research initiative evaluating two types of radiation therapy approved by the U.S. Food & Drug Administration for the treatment of breast cancer.
The Willis-Knighton Cancer Center has added cone beam computed tomography (CBCT) to its ProteusONE compact proton therapy solution. This is the first FDA approved CBCT for compact proton therapy to be used for treatment of a breast cancer patient.
WK Eye Institute surgeons Christopher Shelby, MD, and Wyche T. Coleman III, MD, are the first in our region to offer the iStent® Trabecular Micro-Bypass Stent as a treatment option to reduce eye pressure for patients who have both cataracts and glaucoma.
Willis-Knighton offers multiple convenient locations to serve you. Click here to view all of our locations.
View photos of recent additions to the Wee Kare Nursery.
Enjoy reading local features and information about Willis-Knighton and The Oaks of Louisiana in this national magazine.